Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?The Motley Fool • 10/18/26
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026Business Wire • 10/15/26
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?Zacks Investment Research • 10/15/26
Big pharma stocks near all-time highs as tech selloff pushes investors toward safer betsMarket Watch • 10/15/26
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should KnowZacks Investment Research • 10/02/26
Gilead Sciences (GILD) Declines More Than Market: Some Information for InvestorsZacks Investment Research • 09/30/26
Latin America's PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHFBusiness Wire • 09/17/26
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to KnowZacks Investment Research • 09/17/26
Gilead Expands Lenacapavir Access With New PAHO Deal in Latin AmericaZacks Investment Research • 09/16/26
Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV PreventionBusiness Wire • 09/16/26
Gilead Sciences, Inc. (GILD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/15/26
Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the CaribbeanBusiness Wire • 09/15/26
Gilead Sciences (GILD) Gains As Market Dips: What You Should KnowZacks Investment Research • 09/14/26
Gilead Sciences, Inc. (GILD) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference TranscriptSeeking Alpha • 09/10/26